American Journal of Cardiovascular Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A  Systematic Review and Meta-analysis
ConclusionIn this pooled meta-analytical synthesis of studies comprising both real-world and randomized controlled data, the use of DOAC analogs in patients with atrial fibrillation and low bodyweight (< 60 kg or BMI< 18 kg/m2) was associated with a significant reduction in risks of stroke and major bleeding compared with patient cohorts stabilized on warfarin-based therapy. There was uncertainty regarding the composite outcome and mortality point estimate between these two anticoagulation strategies. This finding helps to resolve the uncertainty associated with the use of DOACs in this cohort. Additionally, it sugge...
Source: American Journal of Cardiovascular Drugs - February 22, 2024 Category: Cardiology Source Type: research

Management of Hypertension in the Asia-Pacific Region: A Structured Review
This article reviews available evidence regarding hypertension management in the Asia-Pacific region, focussing on five research questions that deal with specific aspects: blood pressure (BP) control, guideline recommendations, role of renin –angiotensin–aldosterone system (RAAS) inhibitors in clinical practice, pharmacological management and real-world adherence to guideline recommendations. A PubMed search identified 2537 articles, of which 94 were considered relevant. Compared with Europeans, Asians have higher systolic/diastolic /mean arterial BP, with a stronger association between BP and stroke. Calcium channel b...
Source: American Journal of Cardiovascular Drugs - February 8, 2024 Category: Cardiology Source Type: research

Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis
ConclusionsRCT evidence points to a possible benefit in cardiovascular event reduction from aspirin administration, at the cost of increased major bleeding risk. This finding was not confirmed when the existing observational evidence was incorporated. Further research should determine the most appropriate subpopulation of chronic kidney disease patients that would benefit the most from prophylactic aspirin therapy.Registration The study protocol has been prospectively registered and is publicly available from:https://doi.org/10.17504/protocols.io.261ged63jv47/v1. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 1, 2024 Category: Cardiology Source Type: research

Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease
ConclusionsSerum cystatin C is a sensitive renal function biomarker to predict supratherapeutic digoxin concentration in elderly patients with HF and CKD. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 1, 2024 Category: Cardiology Source Type: research

Author ’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research

Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research

SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis
ConclusionOur study results suggest that a higher SAMe-TT2R2 score resulted in a greater reduction of TTR among Asian and all races. The accuracy parameters showed the highest sensitivity for poor TTR at the SAMe-TT2R2 cutoff of ≥ 3 for Asian patients. However, the ability to identify patients likely to have poor TTR was limited. Further research is needed to enhance the risk assessment for poor anticoagulation control with VKAs.RegistrationThe protocol of this systematic review was registered in the International Prospective Register of Scientific Reviews: PROSPERO, registration number CRD42021291865.Graphical Abstract ...
Source: American Journal of Cardiovascular Drugs - January 22, 2024 Category: Cardiology Source Type: research

Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials
ConclusionsPCSK9i was associated with better lipid profile and quality of life of patients and can be recommended as an optimal treatment strategy. Further trials should study combinations of PCSK9i with other lipid-lowering drugs. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 19, 2024 Category: Cardiology Source Type: research

SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 29, 2023 Category: Cardiology Source Type: research

Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature
AbstractCardiac contraction and relaxation require a substantial amount of energy provided by the mitochondria. The failing heart is adenosine triphosphate (ATP)- and creatine-depleted. Studies have found iron is involved in almost every aspect of mitochondrial function, and previous studies have shown myocardial iron deficiency in heart failure (HF). Many clinicians advocated intravenous iron repletion for HF patients meeting the conventional criteria for systemic iron deficiency. While clinical trials showed improved quality of life, iron repletion failed to significantly impact survival or significant cardiovascular adv...
Source: American Journal of Cardiovascular Drugs - December 29, 2023 Category: Cardiology Source Type: research

The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
ConclusionRivaroxaban 2.5 mg BID plus ASA compared with ASA alone was cost-effective (high value) in the USA.COMPASS ClinicalTrials.gov identifier: NCT01776424. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 28, 2023 Category: Cardiology Source Type: research

Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection
ConclusionsTimely control of infection, assessment of bleeding and thrombotic risks, and selection of appropriate anticoagulation treatment strategies should be made in older NVAF patients who develop pulmonary infection.Clinical Trials RegistrationChinese Clinical Trial Registry Number ChiCTR2000033144. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 24, 2023 Category: Cardiology Source Type: research

Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis
ConclusionCangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 23, 2023 Category: Cardiology Source Type: research

The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review
ConclusionsSodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide benefits for patients with heart failure along with a host of positive modulatory effects on the cardiovascular system, including reductions in inflammatory properties, hypertension, and left ventricular volume load. Given the clear benefit provided by SGLT2i to patients with cardiovascular disease and a host of positive properties that are expected to be protective for patients with ischemic heart disease, future investigation into the relationship between SGLT2i and outcomes for patients undergoing revascularization is imperat...
Source: American Journal of Cardiovascular Drugs - November 17, 2023 Category: Cardiology Source Type: research

A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension
ConclusionMetformin and sotatercept appear as promising therapeutic drugs for PAH.Clinical Trials RegistrationThis work was registered in PROSPERO (CDR42022340658). (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 9, 2023 Category: Cardiology Source Type: research